Carcinoid Tumor Companies

Neurocrine Biosciences, Received FDA approval for their Afinitor (everolimus) for the treatment of advanced neuroendocrine tumors (NETs), including some types of carcinoid tumors. Continued research on their pipeline of investigational therapies for NETs, including somatostatin analogs and radiopharmaceutical agents.

Ipsen Launched their Somatuline Autogel (lanreotide acetate) for the treatment of carcinoid syndrome in adults. Partnering with research institutions to explore novel approaches for targeted therapies and radioligand therapy for NETs.

Novartis Received FDA approval for Lutathera (lutetium Lu 177 dotatate) for the treatment of inoperable, progressive, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with somatostatin receptor positivity. Investing in research on combination therapies and next-generation radioligand therapies for NETs.

Haemedes Developed and commercialized their Hepamed (octreotide acetate) injection, a somatostatin analog for the treatment of carcinoid syndrome and other NETs. Focusing on improving access to their therapy and providing patient support programs.

Roche Received FDA approval for YELMIO (foneprezil) for the treatment of levodopa-induced dyskinesia in Parkinson's disease, although not directly impacting carcinoid tumors, it highlights their commitment to developing novel therapies for rare diseases. Exploring targeted therapies for NETs based on their ongoing research in oncology and rare diseases.

• Neurocrine Biosciences, Inc. (U.S.)


• Fusion IP plc (U.K)


• Novartis AG (Switzerland)


• Mitsubishi Chemical Holdings Corporation (Japan)


• Johnson & Johnson (U.S.)


• GlaxoSmithKline Plc (U.S.)


• Cadila Healthcare (India)


• Sanofi (France)


• Macleods Pharmaceuticals (India)


• GlaxoSmithKline Plc. (U.K)


• Allergan (Ireland)


• Abbott (U.S.)


• Hoffmann-La Roche Ltd. (Switzerland)


• Eli Lilly and Company (U.S.)


• AstraZeneca Plc. (U.K)


• Merck & Co., Inc. (U.S.)